Fulgent Genetics, Inc.

NASDAQ:FLGT

Medical - Diagnostics & Research

Healthcare
$25.13 +1.89%

+$0.33 today

Market cap
$702.11M
Beta
0.92
P/E (TTM)
-7.5
EPS (TTM)
-$2.39
52W Low $13.46High $31.04

Volume 0.39M

Average 0.55M

FLGT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Fulgent Genetics, Inc.NASDAQ: FLGT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $14.18M rose 14.4% year over year, ahead of the +11.9% change in trailing-twelve-month research & development. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +23.1% a year.

Context

  • Research & development amounted to 16.7% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +14.4% holds above the trailing-twelve-month pace of +11.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.18M+0.0% QoQ
Last fiscal yearDec 2025
$53.91M+10.4% YoY
LTMMar 2026
$55.69M+11.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.4%——
1 year+10.4%——
3-year CAGR+23.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
53.91M USD
Year-over-year change
+10.4%
4-year CAGR
+22.1%

Research & Development vs competitors

How FLGT compares with its peers on the latest reported figures

  • FLGT's LTM Mar 2026 research & development of $55.69M is the 6th highest of the 8 companies compared; the peer median is $83.32M.
  • Its year-over-year change of +11.9% is the 4th highest of 8, against a peer median of +9.5%.
  • Research & development amounts to 17.4% of revenue for FLGT, versus a peer median of 18.3%.
FLGT Competitors Peer median
Research & Development for FLGT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NTRANatera, Inc.LTM Jun 2026$787.38M +56.9%+25.4%29.1%
GHGuardant Health, Inc.LTM Sep 2026$386.67M +7.6%-0.9%30.2%
MYGNMyriad Genetics, Inc.LTM Mar 2026$106.4M -7.7%+7.7%12.8%
WGSGeneDx Holdings Corp.LTM Jun 2026$83.32M +64.3%-5.8%18.3%
BLLNBillionToOne, Inc.LTM Jun 2026$59.21M +38.6%—14.9%
FLGTFulgent Genetics, Inc.LTM Mar 2026$55.69M +11.9%+23.1%17.4%
PSNLPersonalis, Inc.LTM Mar 2026$52.16M +6.9%-8.2%80.9%
NEONeoGenomics, Inc.LTM Jun 2026$38.17M +9.5%+6.9%5.0%
FRNMFreenome, Inc. Common stock—— ———
Peer median (excluding FLGT) $83.32M+9.5%+3.0%18.3%

Competitors are the stored peer set for FLGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue992.58M618.97M289.21M283.47M322.67M
Cost of Revenue215.53M252.07M184.76M176.26M191.8M
Gross Profit777.05M366.9M104.46M107.22M130.88M
Gross Margin78.3%59.3%36.1%37.8%40.6%
Research & Development24.22M28.91M41.44M48.82M53.91M
Selling, General & Admin75.17M149.99M130.47M124.35M160.04M
Operating Expenses101.1M188.37M299.99M181.13M221.97M
Depreciation & Amortization11M32.66M26.14M24.93M24.12M
EBITDA692.04M217.7M(147.45M)(26.86M)(45.83M)
EBITDA Margin69.7%35.2%-51.0%-9.5%-14.2%
Operating Income675.95M178.53M(195.53M)(73.92M)(91.1M)
Operating Margin68.1%28.8%-67.6%-26.1%-28.2%
Interest Income1.35M5.62M21.61M31.3M30.92M
Interest Expense01.01M488K170K75K
Other Income / Expenses5.08M5.5M21.44M21.96M21.07M
Income Before Tax681.03M184.03M(174.09M)(51.96M)(70.03M)
Pre-Tax Margin68.6%29.7%-60.2%-18.3%-21.7%
Income Tax Expense174.8M42.1M1.15M(8.14M)(8.39M)
Net Income507.36M143.4M(167.83M)(42.71M)(60.51M)
Net Margin51.1%23.2%-58.0%-15.1%-18.8%
EPS (Basic)17.134.76(5.63)(1.41)(1.97)
EPS (Diluted)16.264.63(5.63)(1.41)(1.97)
Weighted Avg Shares29.41M30.1M29.78M30.24M30.78M
Weighted Avg Shares (Diluted)30.98M30.96M29.78M30.24M30.78M

Fulgent Genetics, Inc.

NASDAQ:FLGT

Intrinsic Alpha fair value

Locked

Current Price

$25.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.